Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.

• Prophylaxis for venous thromboembolism is recommended for at least 10 days after total knee arthroplasty; oral regimens could enable shorter hospital stays. We aimed to test the efficacy and safety of oral rivaroxaban for the prevention of venous thromboembolism after total knee arthroplasty.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kirurgi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Surgery (hsv//eng)

Nyckelord

Administration

Oral

Aged

Analysis of Variance

Anticoagulants

therapeutic use

Arthroplasty

Replacement

Knee

adverse effects

Double-Blind Method

Enoxaparin

therapeutic use

Female

Follow-Up Studies

Hemorrhage

chemically induced

epidemiology

Humans

Incidence

Male

Middle Aged

Morpholines

adverse effects

therapeutic use

Phlebography

Risk Reduction Behavior

Sensitivity and Specificity

Thiophenes

adverse effects

therapeutic use

Treatment Outcome

Venous Thrombosis

epidemiology

etiology

prevention & control

radiography

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)